GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetic Technologies Ltd (STU:DU8) » Definitions » Return-on-Tangible-Asset

Genetic Technologies (STU:DU8) Return-on-Tangible-Asset : 0.00% (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Genetic Technologies Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Genetic Technologies's annualized Net Income for the quarter that ended in Dec. 2023 was €0.00 Mil. Genetic Technologies's average total tangible assets for the quarter that ended in Dec. 2023 was €3.83 Mil. Therefore, Genetic Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was 0.00%.

The historical rank and industry rank for Genetic Technologies's Return-on-Tangible-Asset or its related term are showing as below:

During the past 13 years, Genetic Technologies's highest Return-on-Tangible-Asset was -36.67%. The lowest was -161.19%. And the median was -67.21%.

STU:DU8's Return-on-Tangible-Asset is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -9.45
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Genetic Technologies Return-on-Tangible-Asset Historical Data

The historical data trend for Genetic Technologies's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetic Technologies Return-on-Tangible-Asset Chart

Genetic Technologies Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -132.43 -66.59 -37.18 -37.94 -83.83

Genetic Technologies Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Genetic Technologies's Return-on-Tangible-Asset

For the Diagnostics & Research subindustry, Genetic Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genetic Technologies's Return-on-Tangible-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Genetic Technologies's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Genetic Technologies's Return-on-Tangible-Asset falls into.



Genetic Technologies Return-on-Tangible-Asset Calculation

Genetic Technologies's annualized Return-on-Tangible-Asset for the fiscal year that ended in Jun. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-7.279/( (10.417+6.95)/ 2 )
=-7.279/8.6835
=-83.83 %

Genetic Technologies's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=0/( (0+3.834)/ 1 )
=0/3.834
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Genetic Technologies  (STU:DU8) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Genetic Technologies Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Genetic Technologies's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Genetic Technologies (STU:DU8) Business Description

Traded in Other Exchanges
Address
60-66 Hanover Street, Fitzroy, Melbourne, VIC, AUS, 3065
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

Genetic Technologies (STU:DU8) Headlines

No Headlines